Bausch+Lomb IPO Presentation Deck
Global leader with iconic portfolio of brands
Revenue¹
TAM / CAGR²
Key Stats
Key Products
BAUSCH+ LOMB
-$2.3B
$16B/-4%
7 Franchises each generating
over $100M in revenue
#1 in key emerging markets³
Vision Care
PreserVision. INFUSE LUMIFY
REDNESS BELIEVER EYE CROPS
AUSCH LOMB
re-
nu
Biotrue
Boston Artelac
Source: Third party market research and management estimates
1. For the year ended December 31, 2021
2. Expected market CAGR 2019-2025
3. Includes China, Thailand and India, representing -40% of the world's population
Ophthalmic Pharmaceuticals
$704M
$26B/-4%
Industry leading broad portfolio of
largest ocular categories
Transformational growth
opportunity driven by new
categories and new products
WYZATK
La Boka
Visudyne Minims
Surgical
$718M
$8B/-5%
Presence in ~100 Countries
Pipeline well-positioned to
transform portfolio over the
medium term
enVistatoric storz.
Ophthalmic Instruments
O
CALVINE
LUXGOOD
PE
17View entire presentation